The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Eradication of Tumors through Simultaneous Ablation of CD276/B7-H3-Positive Tumor Cells and Tumor Vasculature
Open accessAbstract
SUMMARY Targeting the tumor vasculature with antibody-drug conjugates (ADCs) is a promising anti-cancer strategy that, in order to be realized, must overcome several obstacles, including identification of suitable targets and optimal warheads. Here, we demonstrate that the cell surface protein CD276/B7-H3 is broadly overexpressed by multiple tumor types on both cancer cells and tumor-infiltrating blood vessels, making it a potentially ideal dual-compartment therapeutic target. In preclinical studies CD276-ADCs armed with a conventional MMAE warhead destroyed CD276-positive cancer cells, but were ineffective against tumor vasculature. In contrast, pyrrolobenzodiazepine-conjugated CD276-ADCs killed both cancer cells and tumor vasculature, eradicating large established tumors and metastases, and improving long-term overall survival. CD276 targeted dual-compartment ablation could aid in development of highly selective broad-acting anti-cancer therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tumor angiogenesis: therapeutic implications
Sherwood, L. M., Parris, E. E., & Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197111182852108 · Cited by 10,187
Kerbel, R. S. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0706596 · Cited by 1,948
Genes Expressed in Human Tumor Endothelium
Croix, B. S., Rago, C., Velculescu, V., Traverso, G., Romans, K. E., Montgomery, E., Lal, A., Riggins, G. J., Lengauer, C., Vogelstein, B., et al. (2000) · Science · doi:10.1126/science.289.5482.1197 · Cited by 1,845
Copper-free click chemistry for dynamic in vivo imaging
Baskin, J. M., Prescher, J. A., Laughlin, S. T., Agard, N. J., Chang, P. V., Miller, I. A., Lo, A., Codelli, J. A., & Bertozzi, C. R. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0707090104 · Cited by 1,833
B7-H3: A costimulatory molecule for T cell activation and IFN-γ production
Chapoval, A. I., Ni, J., Lau, J. S., Wilcox, R. A., Flies, D. B., Liu, D., Dong, H., Sica, G. L., Zhu, G., Tamada, K., et al. (2001) · Nature Immunology · doi:10.1038/85339 · Cited by 1,015
Direct derivation of conditionally immortal cell lines from an H-2Kb-tsA58 transgenic mouse.
Jat, P. S., Noble, M. D., Ataliotis, P., Tanaka, Y., Yannoutsos, N., Larsen, L., & Kioussis, D. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.12.5096 · Cited by 744
Building better monoclonal antibody-based therapeutics
Weiner, G. J. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3930 · Cited by 712
The B7 family member B7-H3 preferentially down-regulates T helper type 1–mediated immune responses
Suh, W.-K., Gajewska, B. U., Okada, H., Gronski, M. A., Bertram, E. M., Dawicki, W., Duncan, G. S., Bukczynski, J., Plyte, S., Elia, A., et al. (2003) · Nature Immunology · doi:10.1038/ni967 · Cited by 576
Oh, P., Li, Y., Yu, J., Durr, E., Krasinska, K. M., Carver, L. A., Testa, J. E., & Schnitzer, J. E. (2004) · Nature · doi:10.1038/nature02580 · Cited by 475
Genes that Distinguish Physiological and Pathological Angiogenesis
Seaman, S., Stevens, J., Yang, M. Y., Logsdon, D., Graff-Cherry, C., & St. Croix, B. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.04.017 · Cited by 419
Self-citationKung Sutherland, M. S., Walter, R. B., Jeffrey, S. C., Burke, P. J., Yu, C., Kostner, H., Stone, I., Ryan, M. C., Sussman, D., Lyon, R. P., et al. (2013) · Blood · doi:10.1182/blood-2013-03-491506 · Cited by 391
Li, F., Emmerton, K. K., Jonas, M., Zhang, X., Miyamoto, J. B., Setter, J. R., Nicholas, N. D., Okeley, N. M., Lyon, R. P., Benjamin, D. R., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-1795 · Cited by 340
Self-citationH‐2Kb‐tsA58トランスジェニックマウスから直接に無限増殖細胞系を得る方法
Jat, P., Noble, M., Ataliotis, P., Tanaka, Y., Yannoutsos, N., Larsen, L., & Kioussis, D. (1991) · Cited by 310
Development of an Fc-Enhanced Anti–B7-H3 Monoclonal Antibody with Potent Antitumor Activity
Loo, D., Alderson, R. F., Chen, F. Z., Huang, L., Zhang, W., Gorlatov, S., Burke, S., Ciccarone, V., Li, H., Yang, Y., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0715 · Cited by 284
Self-citationTumor associated endothelial expression of B7-H3 predicts survival in ovarian carcinomas
Zang, X., Sullivan, P. S., Soslow, R. A., Waitz, R., Reuter, V. E., Wilton, A., Thaler, H. T., Arul, M., Slovin, S. F., Wei, J., et al. (2010) · Modern Pathology · doi:10.1038/modpathol.2010.95 · Cited by 249
Jeffrey, S. C., Burke, P. J., Lyon, R. P., Meyer, D. W., Sussman, D., Anderson, M., Hunter, J. H., Leiske, C. I., Miyamoto, J. B., Nicholas, N. D., et al. (2013) · Bioconjugate Chemistry · doi:10.1021/bc400217g · Cited by 245
Evading tumor evasion: Current concepts and perspectives of anti-angiogenic cancer therapy
Abdollahi, A., & Folkman, J. (2010) · Drug Resistance Updates · doi:10.1016/j.drup.2009.12.001 · Cited by 233
Xu, L., Stevens, J., Hilton, M. B., Seaman, S., Conrads, T. P., Veenstra, T. D., Logsdon, D., Morris, H., Swing, D. A., Patel, N. L., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008455 · Cited by 223
Self-citationDorywalska, M., Dushin, R., Moine, L., Farias, S. E., Zhou, D., Navaratnam, T., Lui, V., Hasa-Moreno, A., Casas, M. G., Tran, T.-T., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-1004 · Cited by 216
Bridgeman, V. L., Vermeulen, P. B., Foo, S., Bilecz, A., Daley, F., Kostaras, E., Nathan, M. R., Wan, E., Frentzas, S., Schweiger, T., et al. (2017) · The Journal of Pathology · doi:10.1002/path.4845 · Cited by 214
Chen, R., Hou, J., Newman, E., Kim, Y., Donohue, C., Liu, X., Thomas, S. H., Forman, S. J., & Kane, S. E. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0036 · Cited by 213
Cheang, M. C. U., Treaba, D. O., Speers, C. H., Olivotto, I. A., Bajdik, C. D., Chia, S. K., Goldstein, L. C., Gelmon, K. A., Huntsman, D., Gilks, C. B., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.4155 · Cited by 206
Nomura, N., Pastorino, S., Jiang, P., Lambert, G., Crawford, J. R., Gymnopoulos, M., Piccioni, D., Juarez, T., Pingle, S. C., Makale, M., et al. (2014) · Cancer Cell International · doi:10.1186/1475-2867-14-26 · Cited by 195
The development of pyrrolobenzodiazepines as antitumour agents
Hartley, J. A. (2011) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2011.573477 · Cited by 175
Kuczynski, E. A., Yin, M., Bar-Zion, A., Lee, C. R., Butz, H., Man, S., Daley, F., Vermeulen, P. B., Yousef, G. M., Foster, F. S., et al. (2016) · Journal of the National Cancer Institute · doi:10.1093/jnci/djw030 · Cited by 174
Yu, S.-F., Zheng, B., Go, M., Lau, J., Spencer, S., Raab, H., Soriano, R., Jhunjhunwala, S., Cohen, R., Caruso, M., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2035 · Cited by 168
Modak, S. I., Kramer, K., Gultekin, S. H., Guo, H.-F., & Cheung, N. V. (2001) · PubMed · Cited by 164
Akiyama, K., Ohga, N., Hida, Y., Kawamoto, T., Sadamoto, Y., Ishikawa, S., Maishi, N., Akino, T., Kondoh, M., Matsuda, A., et al. (2012) · The American Journal of Pathology · doi:10.1016/j.ajpath.2011.11.029 · Cited by 154
Strategies and Advancement in Antibody-Drug Conjugate Optimization for Targeted Cancer Therapeutics
Kim, E. G., & Kim, K. M. (2015) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2015.116 · Cited by 151
B7–H3 Ligand Expression by Primary Breast Cancer and Associated With Regional Nodal Metastasis
Arigami, T., Narita, N., Mizuno, R., Nguyen, L., Ye, X., Chung, A. P., Giuliano, A. E., & Hoon, D. S. �. (2010) · Annals of Surgery · doi:10.1097/sla.0b013e3181f1939d · Cited by 146
B7‐H3 and Its Role in Antitumor Immunity
Loos, M., Hedderich, D. M., Friess, H., & Kleeff, J. H. (2010) · Journal of Immunology Research · doi:10.1155/2010/683875 · Cited by 120
Ahmed, M., Cheng, M. H., Zhao, Q., Goldgur, Y., Cheal, S. M., Guo, H.-F., Larson, S. M., & Cheung, N. V. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.679852 · Cited by 117
Zhu, Z., Ramakrishnan, B., Li, J., Wang, Y., Feng, Y., Prabakaran, P., Colantonio, S., Dyba, M., Qasba, P. K., & Dimitrov, D. S. (2014) · mAbs · doi:10.4161/mabs.29889 · Cited by 104
Self-citationImmunoexpression of B7-H3 in endometrial cancer: Relation to tumor T-cell infiltration and prognosis
Brunner, A. H., Hinterholzer, S., RISS, P. A., Heinze, G., & Brustmann, H. (2011) · Gynecologic Oncology · doi:10.1016/j.ygyno.2011.09.012 · Cited by 100
Antibody drug-conjugates targeting the tumor vasculature
Gerber, H., Senter, P. D., & Grewal, I. S. (2009) · mAbs · doi:10.4161/mabs.1.3.8515 · Cited by 69
B7-H3 is a new cancer-specific endothelial marker in clear cell renal cell carcinoma
Qin, X., Zhang, H., Ye, D., Dai, B., Zhu, Y., & Shi, G. (2013) · OncoTargets and Therapy · doi:10.2147/ott.s53565 · Cited by 69
Construction of a Large Naïve Human Phage-Displayed Fab Library Through One-Step Cloning
Zhu, Z., & Dimitrov, D. S. (2008) · Methods in molecular biology · doi:10.1007/978-1-59745-554-1_6 · Cited by 54
Self-citationNovel Anti-TM4SF1 Antibody–Drug Conjugates with Activity against Tumor Cells and Tumor Vasculature
Visintin, A., Knowlton, K. M., Tyminski, E., Lin, C., Zheng, X., Marquette, K., Jain, S., Tchistiakova, L., Li, D., O’Donnell, C. J., et al. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0188 · Cited by 45
Xiao, L., Harrell, J. C., Perou, C. M., & Dudley, A. C. (2013) · Angiogenesis · doi:10.1007/s10456-013-9409-y · Cited by 26
Antibody-drug conjugates targeting prostate-specific membrane antigen
Olson, W. C., & Israel, R. J. (2014) · Frontiers in bioscience · doi:10.2741/4193 · Cited by 20
PSMA ADC for progressive glioblastoma: Phase II Brown University Oncology Research Group Study.
Elinzano, H., Hebda, N., Luppe, D., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.2065 · Cited by 12
Cited by
Fibroblast Heterogeneity and Immunosuppressive Environment in Human Breast Cancer
Costa, A., Kieffer, Y., Scholer-Dahirel, A., Pelon, F., Bourachot, B., Cardon, M., Sirven, P., Magagna, I., Fuhrmann, L., Bernard, C., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.01.011 · Cited by 1,705
Targeting Strategies for Tissue-Specific Drug Delivery
Zhao, Z., Ukidve, A., Kim, J., & Mitragotri, S. (2020) · Cell · doi:10.1016/j.cell.2020.02.001 · Cited by 1,099
Advancing therapy for osteosarcoma
Gill, J., & Gorlick, R. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00519-8 · Cited by 876
Glioma targeted therapy: insight into future of molecular approaches
Yang, K., Wu, Z., Zhang, H., Zhang, N., Wu, W., Wang, Z., Dai, Z., Zhang, X., Zhang, L., Peng, Y., et al. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01513-z · Cited by 704
Self-citationMajzner, R. G., Theruvath, J. L., Nellan, A., Heitzeneder, S., Cui, Y., Mount, C. W., Rietberg, S. P., Linde, M. H., Xu, P., Rota, C., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0432 · Cited by 681
Self-citation
Metadata
- Authors
- Seaman, S., Zhu, Z., Saha, S., Zhang, X. M., Yang, M. Y., Hilton, M. B., Morris, K., Szot, C., Morris, H., Swing, D. A., Tessarollo, L., Smith, S. W., Degrado, S., Borkin, D., Jain, N., Scheiermann, J., Feng, Y., Wang, Y., Li, J., Welsch, D., DeCrescenzo, G., Chaudhary, A., Zudaire, E., Klarmann, K. D., Keller, J. R., Dimitrov, D. S., & St. Croix, B.
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2017-04
- Volume
- 31
- Issue
- 4
- Pages
- 501-515.e8
- ISSN
- 1535-6108 (ISSN-L)
- OpenAlex
- W2606786998
- Cited by
- 423
- References
- 41
- FWCI
- 22.15
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.